13 February 2020 in BMC Pediatrics
Background: The aim of this study was to review the effects of developmental care in neonatal intensive care unit (NICU) setting on mental and motor development of preterm infants.Method: We searched PubMed, EMBASE, CINAHL, Scopus, Web of Science and Cochrane library until October 8th 2017, and included randomized controlled trials that assessed effects of developmental care in NICU on mental and motor development of preterm infants at 12 and 24 months of age, using the Bayley scale of infant development in this systematic review. In addition, data were pooled by random effects model and Standardized Mean Difference (SMD) with 95% confidence intervals (CI), calculated for meta-analysis.Results: Twenty one studies were eligible to be included in this systematic review; however, only thirteen studies had data suitable for meta-analysis. According to statistical analysis, developmental care in NICU improved mental developmental index (MDI) (standardized mean difference [SMD] 0.55, 95% confidence interval [CI] 0.23–0.87;p < 0.05), and psychomotor developmental index (PDI) (SMD 0.33, [CI] 95% CI 0.08–0.57;p < 0.05) of BSID at 12 months of age and PDI at 24 months of age (SMD 0.15, 95% CI -0.02–0.32;p < 0.1) of preterm infants. However, the benefit was not detected at 24 months of age on MDI (SMD 0.15, 95% CI -0.05–0.35;p = 0.15).Conclusion: Current evidence suggests that developmental care in only NICU setting could have significant effect on mental and motor development of preterm infants, especially at 12 months of age. However, because of clinical heterogeneity, more studies are needed to evaluate the effects of developmental NICU care in the development of preterm infants.
25 September 2024 in Thorax
Objectives To examine the accuracy and impact of artificial intelligence (AI) software assistance in lung cancer screening using CT. Methods A systematic review of CE-marked, AI-based software for automated detection and analysis of nodules in CT lung cancer screening was conducted. Multiple databases including Medline, Embase and Cochrane CENTRAL were searched from 2012 to March 2023. Primary research reporting test accuracy or impact on reading time or clinical management was included. QUADAS-2 and QUADAS-C were used to assess risk of bias. We undertook narrative synthesis. Results Eleven studies evaluating six different AI-based software and reporting on 19 770 patients were eligible. All were at high risk of bias with multiple applicability concerns. Compared with unaided reading, AI-assisted reading was faster and generally improved sensitivity (+5% to +20% for detecting/categorising actionable nodules; +3% to +15% for detecting/categorising malignant nodules), with lower specificity (−7% to −3% for correctly detecting/categorising people without actionable nodules; −8% to −6% for correctly detecting/categorising people without malignant nodules). AI assistance tended to increase the proportion of nodules allocated to higher risk categories. Assuming 0.5% cancer prevalence, these results would translate into additional 150–750 cancers detected per million people attending screening but lead to an additional 59 700 to 79 600 people attending screening without cancer receiving unnecessary CT surveillance. Conclusions AI assistance in lung cancer screening may improve sensitivity but increases the number of false-positive results and unnecessary surveillance. Future research needs to increase the specificity of AI-assisted reading and minimise risk of bias and applicability concerns through improved study design. PROSPERO registration number CRD42021298449.
29 September 2015 in Iranian Red Crescent Medical Journal
HGHassan Abolghasem Gorji
Background: During the last two decades, the trend of out-of-pocket payments (OOP) for health services by Iranian households has been a matter of concern and it has exposed a significant proportion of them to catastrophic and impoverishing health expenditures. Objectives: The current study aimed to investigate three objectives: First, the mean of out-of-pocket payments among Iranian households for health services; second, the headcount and overshoot measures of catastrophic health expenditure; and finally the level of inequality in its distribution. Materials and Methods: This descriptive study on Iranian rural and urban households was conducted from April to June 2015. The sample sizes were 19437 rural and 18888 urban households that Iranian Statistical Centre (ISC) selected them through a three -step randomized clustered sampling. The headcount and overshoot measures for catastrophic health expenditure were calculated. Also, the concentration index was calculated in order to investigate the inequality in distribution of the mentioned measures. Results: The catastrophic health expenditure headcount ratio varied from 0.5% to 14.3% and from 0.48% to 13.27% for rural and urban households, respectively. Also, the overshoot of catastrophic health expenditure varied from 9.62% to 18.72% and from 8.8% to 17.74% for rural and urban households, respectively. Conclusions: Considering Iran’s economic condition during the last five years, the catastrophic health expenditure headcount ratio was more than 2% in Iran. Keywords: Financial Risk Protection; Out-of-Pocket Expenditure; Catastrophic Health Expenditures; Concentration Index
25 January 2017 in International Journal of Behavioral Medicine
1 May 2025 in Health Technology Assessment
Background: Lung cancer is one of the most common types of cancer and the leading cause of cancer death in the United Kingdom. Artificial intelligence-based software has been developed to reduce the number of missed or misdiagnosed lung nodules on computed tomography images. Objective: To assess the accuracy, clinical effectiveness and cost-effectiveness of using software with artificial intelligence-derived algorithms to assist in the detection and analysis of lung nodules in computed tomography scans of the chest compared with unassisted reading. Design: Systematic review and de novo cost-effectiveness analysis. Methods: Searches were undertaken from 2012 to January 2022. Company submissions were accepted until 31 August 2022. Study quality was assessed using the revised tool for the quality assessment of diagnostic accuracy studies (QUADAS-2), the extension to QUADAS-2 for assessing risk of bias in comparative accuracy studies (QUADAS-C) and the COnsensus-based Standards for the selection of health status Measurement INstruments (COSMIN) checklist. Outcomes were synthesised narratively. Two decision trees were used for cost-effectiveness: (1) a simple decision tree for the detection of actionable nodules and (2) a decision tree reflecting the full clinical pathways for people undergoing chest computed tomography scans. Models estimated incremental cost-effectiveness ratios, cost per correct detection of an actionable nodule, and cost per cancer detected and treated. We undertook scenario and sensitivity analyses. Results: Twenty-seven studies were included. All were rated as being at high risk of bias. Twenty-four of the included studies used retrospective data sets. Seventeen compared readers with and without artificial intelligence software. One reported prospective screening experiences before and after artificial intelligence software implementation. The remaining studies either evaluated stand-alone artificial intelligence or provided only non-comparative evidence. (1) Artificial intelligence assistance generally improved the detection of any nodules compared with unaided reading (three studies; average per-person sensitivity 0.43–0.68 for unaided and 0.79–0.99 for artificial intelligence-assisted reading), with similar or lower specificity (three studies; 0.77–1.00 for unaided and 0.81–0.97 for artificial intelligence-assisted reading). Nodule diameters were similar or significantly larger with semiautomatic measurements than with manual measurements. Intra-reader and inter-reader agreement in nodule size measurement and in risk classification generally improved with artificial intelligence assistance or were comparable to those with unaided reading. However, the effect on measurement accuracy is unclear. (2) Radiologist reading time generally decreased with artificial intelligence assistance in research settings. (3) Artificial intelligence assistance tended to increase allocated risk categories as defined by clinical guidelines. (4) No relevant clinical effectiveness and cost-effectiveness studies were identified. (5) The de novo cost-effectiveness analysis suggested that for symptomatic and incidental populations, artificial intelligence-assisted computed tomography image analysis dominated the unaided radiologist in cost per correct detection of an actionable nodule. However, when relevant costs and quality-adjusted life-years from the full clinical pathway were included, artificial intelligence-assisted computed tomography reading was dominated by the unaided reader. For screening, artificial intelligence-assisted computed tomography image analysis was cost-effective in the base case and all sensitivity and scenario analyses. Limitations: Due to the heterogeneity, sparseness, low quality and low applicability of the clinical effectiveness evidence and the major challenges in linking test accuracy evidence to clinical and economic outcomes, the findings presented here are highly uncertain and provide indicators/frameworks for future assessment. Conclusions: Artificial intelligence-assisted analysis of computed tomography scan images may reduce variability of and improve consistency in the measurement and clinical management of lung nodules. Artificial intelligence may increase nodule and cancer detection but may also increase the number of patients undergoing computed tomography surveillance unnecessarily. No direct comparative evidence was found, and nor was any direct evidence found on clinical outcomes and cost-effectiveness. Artificial intelligence-assisted image analysis may be cost-effective in screening for lung cancer but not for symptomatic populations. However, reliable estimates of cost-effectiveness cannot be obtained with current evidence. Study registration: This study is registered as PROSPERO CRD42021298449. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: NIHR135325) and is published in full in Health Technology Assessment; Vol. 29, No. 14. See the NIHR Funding and Awards website for further award information.